Automated Virtual Reality Cognitive Therapy for People With Psychosis: Protocol for a Qualitative Investigation Using Peer Research Methods.

agoraphobia cognitive therapy implementation mental health peer research psychosis qualitative methods schizophrenia therapy virtual reality

Journal

JMIR research protocols
ISSN: 1929-0748
Titre abrégé: JMIR Res Protoc
Pays: Canada
ID NLM: 101599504

Informations de publication

Date de publication:
25 Oct 2021
Historique:
received: 02 07 2021
accepted: 03 08 2021
revised: 02 08 2021
entrez: 25 10 2021
pubmed: 26 10 2021
medline: 26 10 2021
Statut: epublish

Résumé

Many people with psychosis experience difficulties in everyday social situations. Anxiety can make life challenging, leading to withdrawal. Cognitive therapy, using active in vivo learning, enables people to overcome fears. These treatments are not readily available to people with psychosis. Automated virtual reality (VR) therapy is a potential route to increase accessibility. The gameChange automated VR cognitive therapy is designed to help people overcome anxious avoidance and build confidence in everyday social situations. A virtual coach guides the person through the treatment. Understanding user experience is key to facilitating future implementation. Peer research methods, in which people with lived experience of the issues being studied are involved in collecting and analyzing data, may be useful in developing this understanding. This encourages researchers to draw on their lived experience to explore participant perspectives and co-create knowledge. The primary objective is to use a peer research approach to explore the participant experience of a novel automated VR therapy for anxious social avoidance. This includes understanding (1) the experience of anxious social avoidance in people with psychosis, (2) the experience of the gameChange automated VR cognitive therapy, and (3) any potential impact of the therapy in people's lives. This will inform future implementation strategies. The secondary objective is to explore how peer research can be used to co-create knowledge. Semistructured interviews will be conducted with approximately 25 people with psychosis participating in the gameChange trial (ISRCTN17308399). Participants will be recruited from the five trial centers based in National Health Service mental health trusts across England. Interviews will be conducted by two researchers. One is a peer researcher with similar lived experience to the trial participants. The other has lived experiences of mental health issues that do not directly overlap with those of the trial participants. Interview questions will focus on an individual's experience of anxious social avoidance, experiences of participating in the gameChange VR therapy, and any changes or impact following therapy. The interview schedule was developed in collaboration with the gameChange Lived Experience Advisory Panel (LEAP), comprising 10 project advisors with lived experience of psychosis. Interpretative phenomenological analysis and template analysis will be used to explore individual accounts. The LEAP will contribute to the analysis. Data collection will be conducted from April to September 2021, and analysis will be conducted from June to October 2021. As of September 28, 2021, 20 participants had been interviewed, and coding is underway. The study, employing a peer research approach, may provide a unique insight into the experiences of anxious social avoidance in people with psychosis and its treatment using automated VR therapy. This will inform potential future implementation of VR automated therapies in mental health services. DERR1-10.2196/31742.

Sections du résumé

BACKGROUND BACKGROUND
Many people with psychosis experience difficulties in everyday social situations. Anxiety can make life challenging, leading to withdrawal. Cognitive therapy, using active in vivo learning, enables people to overcome fears. These treatments are not readily available to people with psychosis. Automated virtual reality (VR) therapy is a potential route to increase accessibility. The gameChange automated VR cognitive therapy is designed to help people overcome anxious avoidance and build confidence in everyday social situations. A virtual coach guides the person through the treatment. Understanding user experience is key to facilitating future implementation. Peer research methods, in which people with lived experience of the issues being studied are involved in collecting and analyzing data, may be useful in developing this understanding. This encourages researchers to draw on their lived experience to explore participant perspectives and co-create knowledge.
OBJECTIVE OBJECTIVE
The primary objective is to use a peer research approach to explore the participant experience of a novel automated VR therapy for anxious social avoidance. This includes understanding (1) the experience of anxious social avoidance in people with psychosis, (2) the experience of the gameChange automated VR cognitive therapy, and (3) any potential impact of the therapy in people's lives. This will inform future implementation strategies. The secondary objective is to explore how peer research can be used to co-create knowledge.
METHODS METHODS
Semistructured interviews will be conducted with approximately 25 people with psychosis participating in the gameChange trial (ISRCTN17308399). Participants will be recruited from the five trial centers based in National Health Service mental health trusts across England. Interviews will be conducted by two researchers. One is a peer researcher with similar lived experience to the trial participants. The other has lived experiences of mental health issues that do not directly overlap with those of the trial participants. Interview questions will focus on an individual's experience of anxious social avoidance, experiences of participating in the gameChange VR therapy, and any changes or impact following therapy. The interview schedule was developed in collaboration with the gameChange Lived Experience Advisory Panel (LEAP), comprising 10 project advisors with lived experience of psychosis. Interpretative phenomenological analysis and template analysis will be used to explore individual accounts. The LEAP will contribute to the analysis.
RESULTS RESULTS
Data collection will be conducted from April to September 2021, and analysis will be conducted from June to October 2021. As of September 28, 2021, 20 participants had been interviewed, and coding is underway.
CONCLUSIONS CONCLUSIONS
The study, employing a peer research approach, may provide a unique insight into the experiences of anxious social avoidance in people with psychosis and its treatment using automated VR therapy. This will inform potential future implementation of VR automated therapies in mental health services.
INTERNATIONAL REGISTERED REPORT IDENTIFIER (IRRID) UNASSIGNED
DERR1-10.2196/31742.

Identifiants

pubmed: 34694236
pii: v10i10e31742
doi: 10.2196/31742
pmc: PMC8576557
doi:

Types de publication

Journal Article

Langues

eng

Pagination

e31742

Subventions

Organisme : Wellcome Trust
Pays : United Kingdom

Informations de copyright

©Jessica Bond, Dan Robotham, Alexandra Kenny, Vanessa Pinfold, Thomas Kabir, Humma Andleeb, Michael Larkin, Jennifer L Martin, Susan Brown, Aislinn D Bergin, Ariane Petit, Laina Rosebrock, Sinéad Lambe, Daniel Freeman, Felicity Waite. Originally published in JMIR Research Protocols (https://www.researchprotocols.org), 25.10.2021.

Références

Lancet Psychiatry. 2018 Aug;5(8):625-632
pubmed: 30007519
Br J Psychol. 2000 Feb;91 ( Pt 1):1-20
pubmed: 10717768
Int J Qual Health Care. 2007 Dec;19(6):349-57
pubmed: 17872937
Trials. 2019 Jan 29;20(1):87
pubmed: 30696471
Behav Res Ther. 1999 Jul;37 Suppl 1:S5-27
pubmed: 10402694
Br J Psychiatry. 2016 Jul;209(1):62-7
pubmed: 27151071
BMJ Open. 2019 Aug 27;9(8):e031606
pubmed: 31462489
J Psychopharmacol. 2019 Oct;33(10):1264-1273
pubmed: 31294651
Health Expect. 2013 Dec;16(4):e89-99
pubmed: 22958162
Qual Health Res. 2014 Jan;24(1):136-44
pubmed: 24413767
J Anxiety Disord. 2019 Jan;61:27-36
pubmed: 30287083
Lancet Psychiatry. 2018 Mar;5(3):217-226
pubmed: 29429948
Schizophr Res. 2019 Sep;211:44-50
pubmed: 31326234
Qual Res Psychol. 2015 Apr 3;12(2):202-222
pubmed: 27499705
Health Expect. 2010 Jun;13(2):185-94
pubmed: 20536538
J Adv Nurs. 2017 Jan;73(1):265-278
pubmed: 27509545

Auteurs

Jessica Bond (J)

McPin Foundation, London, United Kingdom.

Dan Robotham (D)

McPin Foundation, London, United Kingdom.

Alexandra Kenny (A)

McPin Foundation, London, United Kingdom.

Vanessa Pinfold (V)

McPin Foundation, London, United Kingdom.

Thomas Kabir (T)

McPin Foundation, London, United Kingdom.

Humma Andleeb (H)

Research Department of Clinical, Educational and Health Psychology, Psychology and Language Sciences, Faculty of Brain Sciences, UCL, London, United Kingdom.

Michael Larkin (M)

School of Psychology, Aston University, Birmingham, United Kingdom.

Jennifer L Martin (JL)

School of Medicine, University of Nottingham, Nottingham, United Kingdom.
National Institute for Health Research Nottingham Biomedical Research Centre, Nottingham, United Kingdom.
National Institute for Health Research Mindtech Co-operative, Nottingham, United Kingdom.

Susan Brown (S)

School of Medicine, University of Nottingham, Nottingham, United Kingdom.
National Institute for Health Research Nottingham Biomedical Research Centre, Nottingham, United Kingdom.
National Institute for Health Research Mindtech Co-operative, Nottingham, United Kingdom.

Aislinn D Bergin (AD)

School of Medicine, University of Nottingham, Nottingham, United Kingdom.
National Institute for Health Research Nottingham Biomedical Research Centre, Nottingham, United Kingdom.
National Institute for Health Research Mindtech Co-operative, Nottingham, United Kingdom.

Ariane Petit (A)

Department of Psychiatry, University of Oxford, Oxford, United Kingdom.
Oxford Health National Health Service Foundation Trust, Oxford, United Kingdom.
National Institute for Health Research Oxford Health Biomedical Research Centre, Oxford, United Kingdom.

Laina Rosebrock (L)

Department of Psychiatry, University of Oxford, Oxford, United Kingdom.
Oxford Health National Health Service Foundation Trust, Oxford, United Kingdom.
National Institute for Health Research Oxford Health Biomedical Research Centre, Oxford, United Kingdom.

Sinéad Lambe (S)

Department of Psychiatry, University of Oxford, Oxford, United Kingdom.
Oxford Health National Health Service Foundation Trust, Oxford, United Kingdom.
National Institute for Health Research Oxford Health Biomedical Research Centre, Oxford, United Kingdom.

Daniel Freeman (D)

Department of Psychiatry, University of Oxford, Oxford, United Kingdom.
Oxford Health National Health Service Foundation Trust, Oxford, United Kingdom.
National Institute for Health Research Oxford Health Biomedical Research Centre, Oxford, United Kingdom.

Felicity Waite (F)

Department of Psychiatry, University of Oxford, Oxford, United Kingdom.
Oxford Health National Health Service Foundation Trust, Oxford, United Kingdom.
National Institute for Health Research Oxford Health Biomedical Research Centre, Oxford, United Kingdom.

Classifications MeSH